

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM748193

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Bank of New York Mellon		07/15/2022	National Banking Association: NEW YORK
RECEIVING PARTY DATA			
Name:	EPI Health, LLC		
Street Address:	134 Columbus Street		
City:	Charleston		
State/Country:	SOUTH CAROLINA		
Postal Code:	29403		
Entity Type:	Limited Liability Company: SOUTH CAROLINA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2275169	CLODERM	
CORRESPONDENCE DATA			
Fax Number:	2158325745		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	215-569-5745		
Email:	megan.spitz@blankrome.com		
Correspondent Name:	Megan E. Spitz		
Address Line 1:	Blank Rome LLP		
Address Line 2:	One Logan Square, 8th Floor		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103		
ATTORNEY DOCKET NUMBER:	152949-00109		
NAME OF SUBMITTER:	Megan E. Spitz		
SIGNATURE:	/megan e. spitz/		
DATE SIGNED:	08/12/2022		
Total Attachments: 5			
source=Cloderm - Partial Trademark Release (BONY_BHA) Executed#page1.tif			
source=Cloderm - Partial Trademark Release (BONY_BHA) Executed#page2.tif			
source=Cloderm - Partial Trademark Release (BONY_BHA) Executed#page3.tif			

OP \$40.00 2275169

source=Cloderm - Partial Trademark Release (BONY_BHA) Executed#page4.tif

source=Cloderm - Partial Trademark Release (BONY_BHA) Executed#page5.tif

RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

This RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS (this "Release") is entered into as of July 21, 2022 by The Bank of New York Mellon, a New York banking corporation, as Collateral Agent for the Noteholder Secured Parties (the "Assignor"), in favor of EPI Health, LLC, a South Carolina limited liability company (the "Assignee"), being successor in interest to Promius Pharma LLC, being successor in interest to Bausch Health Americas, Inc. (f/k/a Valeant Pharmaceuticals International) (successor-in-interest to Coria Laboratories, Ltd. (the "Grantor")). Capitalized terms used in this Release but not defined herein shall have the respective meanings ascribed to such terms in the Security Agreements or Trademark Security Agreements (each as defined below), as applicable.

WHEREAS, reference is made to (i) that certain U.S. Pledge and Security Agreement dated as of March 21, 2017 (as it may have been amended, restated, supplemented or otherwise modified prior to the date hereof, the "March Security Agreement"), between the other grantors party thereto, the Grantor and the Assignor; (ii) that certain U.S. Pledge and Security Agreement dated as of October 17, 2017, between the other grantors party thereto, the Grantor and the Assignor (as it may have been amended, restated, supplemented or otherwise modified prior to the date hereof, the "October Security Agreement" and together with the March Security Agreement, the "Security Agreements"); (iii) that certain Trademark Security Agreement, dated as of July 17, 2017 between the Assignor (as Collateral Agent) and the Grantor and other grantors party thereto (the "March Bond TMSA"); (iv) that certain Trademark Security Agreement, dated as of February 13, 2018 between the Assignor (as Collateral Agent) and the Grantor and other grantors party thereto (the "October Bond TMSA" and, together with the March Bond TMSA, the "Trademark Security Agreements"); and (v) that certain Assignment of Trademark, dated as of August 21, 2019 by and between the Grantor and Promius Pharma LLC (the "Assignment of Trademark");

WHEREAS, pursuant to the terms and conditions of each Trademark Security Agreement, the Grantor granted to the Assignor, for the benefit of the Secured Parties, a security interest in and continuing lien on all of the Grantor's right, title and interest in, to and under the following, in each case whether then owned or thereafter acquired by the Grantor or in which the Grantor then had or thereafter acquired any right, title or interest and wherever the same may be located (collectively, the "Trademark Collateral");

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached to the Trademark Security Agreement, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without

limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world;

WHEREAS, the March Bond TMSA was recorded with the United States Patent and Trademark Office on October 4, 2017 at Reel 006172, Frame 0568, the October Bond TMSA was recorded with the United States Patent and Trademark Office on February 26, 2018 at Reel 006280, Frame 0211, and the Assignment of Trademark was recorded with the United States Patent and Trademark Office on August 22, 2019 at Reel 6726, Frame 0787;

WHEREAS, Bausch Health Americas, Inc., a Delaware corporation and a successor to the Grantor assigned the trademark set forth on Schedule I hereto (the "Specified Trademark") to Promius Pharma LLC, a Delaware limited liability company ("Promius") pursuant to the Assignment of Trademark;

WHEREAS, pursuant to that certain Officer's Certificate dated as of July 20, 2022 (the "Certificate"), the Grantor has certified to the Assignor that Promius assigned the Specified Trademark to the Assignee pursuant to that certain Trademark Assignment Agreement, dated as of February 20, 2020, by and between Promius as assignor and the Assignee as assignee; and

WHEREAS, the Assignor, solely in reliance on the representations, warranties and certifications made pursuant to the Certificate and without independent investigation, has agreed to terminate and release its security interest solely in the Specified Trademarks and Specified Trademark Collateral (as defined below) related thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor, on behalf of itself, its successors, legal representatives and assigns and any noteholders for which the Assignor acted as security or collateral agent hereby unconditionally terminates, releases, discharges and reassigns to the Assignee fully, without representation, warranty or recourse, its security interest in and continuing lien on all of the Assignee's right, title and interest in, to and under (i) the Specified Trademarks, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto (but excluding, for the avoidance of doubt, Proceeds from the sale by the Assignee of the Specified Trademarks as referenced in the Certificate), and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Specified Trademark Collateral").

The Assignor hereby acknowledges that the Assignee or the Assignee's authorized representative may record this Release with the United States Patent and Trademark Office ("USPTO") and any other offices as may be necessary to carry out the intention of this Release.

The Assignor shall execute and deliver any and all documents or other instruments reasonably requested by the Assignee, and at the Assignee's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

Delivery of an executed signature page to this Release by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of an original signature.


For the avoidance of any doubt, this Release is strictly limited solely and only to the Specified Trademark Collateral and to no other Trademark Collateral. The Assignor continues to maintain, without interruption or impairment, its security interest in all of the Assignee's right, title and interest in, to and under all Trademark Collateral other than the Specified Trademark Collateral. The provisions of the Trademark Security Agreement and the Security Agreements shall, except as modified by this Release, continue in full force and effect.

**THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND
ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK
WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.**

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Assignor has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

THE BANK OF NEW YORK MELLON,
as Collateral Agent

By:  _____
Digitally signed by
Lisa Sollitto
Date: 2022.07.15
12:41:45 -04'00'

Name: Lisa Sollitto
Title: Vice President

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

Specified Trademarks

No.	Jurisdiction	Registered Owner	Mark	App. No.	Reg. No.	App. Date	Reg. Date
1.	United States	EPI HEALTH, LLC	CLODERM		02/18/1997	2275169	09/07/1999